News

TMR : Tumor Necrosis Factor Receptor Superfamily Member 18 Pipeline Report: Reviews Key Companies Involved and Enlists all their Major and Minor Projects

Tumor Necrosis Factor Receptor Superfamily Member 18 pipeline Target constitutes close to 14 molecules. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 5 and 3 respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Hematological Tumor, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Breast Cancer, Colorectal Cancer, Endometrial Cancer, Fallopian Tube Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ocular Melanoma, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Renal Cell Carcinoma and Squamous Cell Carcinoma.

Report Source: https://www.themarketreports.com/report/tumor-necrosis-factor-receptor-superfamily-member-18-glucocorticoid-induced-tumor-necrosis-factor-receptor-or-activation-inducible-tnfr-family-receptor-or-glucocorticoid-induced-tnfr-related-protein-or-cd357-or-tnfrsf18-pipeline-review-h1

Scope

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tumor Necrosis Factor Receptor Superfamily Member 18 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 18 targeted therapeutics

Purchase this report at: https://www.themarketreports.com/report/buy-now/1470892

Reasons To Buy

  • Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 18
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 18 development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

  • Ablynx NV
  • Alligator Bioscience AB
  • Apogenix AG
  • Avacta Life Sciences Ltd
  • Bristol-Myers Squibb Co
  • Checkpoint Therapeutics Inc
  • GigaGen Inc
  • Incyte Corp
  • Leap Therapeutics Inc
  • Merck & Co Inc
  • Novartis AG
  • Regeneron Pharmaceuticals Inc

Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/1470892